IN2014KN02740A - - Google Patents

Info

Publication number
IN2014KN02740A
IN2014KN02740A IN2740KON2014A IN2014KN02740A IN 2014KN02740 A IN2014KN02740 A IN 2014KN02740A IN 2740KON2014 A IN2740KON2014 A IN 2740KON2014A IN 2014KN02740 A IN2014KN02740 A IN 2014KN02740A
Authority
IN
India
Prior art keywords
hiv
provides
polypeptidestabilized
polypeptideor
conformation
Prior art date
Application number
Other languages
English (en)
Inventor
Andrea Carfi
Antu Dey
Aemro Kassa
Indresh Srivastava
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014KN02740A publication Critical patent/IN2014KN02740A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171Demonstrated in vivo effect
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2740KON2014 2012-06-18 2013-06-17 IN2014KN02740A (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661050P 2012-06-18 2012-06-18
PCT/EP2013/062553 WO2013189901A1 (en) 2012-06-18 2013-06-17 Stabilized gp120

Publications (1)

Publication Number Publication Date
IN2014KN02740A true IN2014KN02740A (https=) 2015-05-08

Family

ID=48628698

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2740KON2014 IN2014KN02740A (https=) 2012-06-18 2013-06-17

Country Status (14)

Country Link
US (1) US20150183835A1 (https=)
EP (1) EP2861249A1 (https=)
JP (1) JP2015521592A (https=)
KR (1) KR20150023735A (https=)
CN (1) CN104619338A (https=)
AU (1) AU2013279456A1 (https=)
CA (1) CA2876762A1 (https=)
IL (1) IL235898A0 (https=)
IN (1) IN2014KN02740A (https=)
MX (1) MX2014014682A (https=)
RU (1) RU2015101081A (https=)
SG (1) SG11201407995RA (https=)
WO (1) WO2013189901A1 (https=)
ZA (1) ZA201408840B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016037154A1 (en) * 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant hiv-1 envelope proteins and their use
MX388708B (es) * 2014-09-23 2025-03-20 Boehringer Ingelheim Animal Health Usa Inc Vacunas recombinantes contra fmdv y sus usos.
EP3069730A3 (en) * 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3426291A1 (en) 2016-03-09 2019-01-16 The U.S.A. as represented by the Secretary, Department of Health and Human Services Recombinant hiv-1 envelope proteins and their use
CN118562016A (zh) 2016-10-21 2024-08-30 艾尔特生物科技公司 基于多聚体il-15的分子
EP3697440A1 (en) 2017-10-16 2020-08-26 The United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant hiv-1 envelope proteins and their use
CN109851664A (zh) * 2017-11-30 2019-06-07 清华大学 一种基于抗体反向表位设计的蛋白质及其在制备抗艾滋病病毒疫苗中的应用
US11311603B2 (en) 2018-06-19 2022-04-26 Nantcell, Inc. HIV treatment compositions and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786488B1 (fr) * 1998-11-27 2003-04-25 Orstom Mutants de la gp120 et leurs applications biologiques
CA2370517A1 (en) * 1999-06-25 2001-01-04 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
BRPI0815743A2 (pt) * 2007-08-24 2015-02-18 Novartis Ag Proteínas hiv env com modificações no laço v3
AU2010298025B2 (en) * 2009-09-25 2016-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use

Also Published As

Publication number Publication date
IL235898A0 (en) 2015-01-29
RU2015101081A (ru) 2016-08-10
ZA201408840B (en) 2016-08-31
CN104619338A (zh) 2015-05-13
JP2015521592A (ja) 2015-07-30
EP2861249A1 (en) 2015-04-22
SG11201407995RA (en) 2015-01-29
AU2013279456A1 (en) 2014-12-18
US20150183835A1 (en) 2015-07-02
MX2014014682A (es) 2015-03-04
CA2876762A1 (en) 2013-12-27
KR20150023735A (ko) 2015-03-05
WO2013189901A1 (en) 2013-12-27

Similar Documents

Publication Publication Date Title
IN2014KN02740A (https=)
CY1124043T1 (el) Εξουδετερωτικα αντισωματα του ανθρωπινου ιου της ανοσοανεπαρκειας και μεθοδοι χρησης αυτων
WO2013006688A3 (en) N-terminal deleted gp120 immunogens
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
EA201290956A1 (ru) Вакцина против вич
WO2013085550A3 (en) V1v2 immunogens
NZ732391A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
PH12015501156A1 (en) Pharmaceutical compositions
PH12015502539B1 (en) Cenicriviroc compositions and methods of making and using the same
PH12013502442A1 (en) Inactivated dengue virus vaccine
IN2015DN03202A (https=)
WO2011106100A3 (en) Method of inducing the production of protective anti-hiv-1 antibodies
WO2014160747A3 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
IN2014CH00395A (https=)
UA118542C2 (uk) Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197
ZA201307069B (en) Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv
WO2015086738A3 (en) Hiv vaccine
AU2013235442A8 (en) Stable peptide mimetics of the HIV-1 gp41 pre-hairpin intermediate
IN2014DN09445A (https=)
WO2012139097A3 (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2014210082A3 (en) Camptothecin derivatives as anti-hiv agents and methods of identifying agents that disrupt vif self-association
MX385188B (es) Vacuna de rinitis equina.
WO2011139385A3 (en) Genetic signatures in hiv-1 subtype c envelope glycoproteins
WO2012071521A3 (en) Adjuvant